177 related articles for article (PubMed ID: 38561208)
1. Nonhormone therapies for vasomotor symptom management.
Iyer TK; Fiffick AN; Batur P
Cleve Clin J Med; 2024 Apr; 91(4):237-244. PubMed ID: 38561208
[TBL] [Abstract][Full Text] [Related]
2. The 2023 nonhormone therapy position statement of The North American Menopause Society.
“The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society” Advisory Panel
Menopause; 2023 Jun; 30(6):573-590. PubMed ID: 37252752
[TBL] [Abstract][Full Text] [Related]
3. Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms.
Umland EM
J Manag Care Pharm; 2008 Apr; 14(3 Suppl):14-9. PubMed ID: 18439062
[TBL] [Abstract][Full Text] [Related]
4. Vasomotor symptoms: viewpoint from the Indian subcontinent and management of a common menopausal problem.
Shah D; Agrawal S
Semin Reprod Med; 2010 Sep; 28(5):388-95. PubMed ID: 20865655
[TBL] [Abstract][Full Text] [Related]
5. Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors.
Santen RJ; Stuenkel CA; Davis SR; Pinkerton JV; Gompel A; Lumsden MA
J Clin Endocrinol Metab; 2017 Oct; 102(10):3647-3661. PubMed ID: 28934376
[TBL] [Abstract][Full Text] [Related]
6. Low use of effective and safe therapies for moderate to severe menopausal symptoms: a cross-sectional community study of Australian women.
Worsley R; Bell RJ; Gartoulla P; Davis SR
Menopause; 2016 Jan; 23(1):11-7. PubMed ID: 26240945
[TBL] [Abstract][Full Text] [Related]
7. Menopause review: Emerging treatments for menopausal symptoms.
Patel B; S Dhillo W
Best Pract Res Clin Obstet Gynaecol; 2022 May; 81():134-144. PubMed ID: 34965909
[TBL] [Abstract][Full Text] [Related]
8. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society.
Menopause; 2015 Nov; 22(11):1155-72; quiz 1173-4. PubMed ID: 26382310
[TBL] [Abstract][Full Text] [Related]
9. Treating vasomotor symptoms of menopause: the nurse practitioner's perspective.
Alexander IM; Moore A
J Am Acad Nurse Pract; 2007 Mar; 19(3):152-63. PubMed ID: 17341283
[TBL] [Abstract][Full Text] [Related]
10. Assessment of women's treatment preferences for vasomotor symptoms due to menopause.
Shiozawa A; Thurston RC; Cook E; Yang H; King DD; Kristy RM; Mancuso S
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(10):1117-1128. PubMed ID: 37650213
[TBL] [Abstract][Full Text] [Related]
11. Hormone Therapy for Relieving Postmenopausal Vasomotor Symptoms: A Systematic Review.
Abdi F; Mobedi H; Mosaffa N; Dolatian M; Ramezani Tehrani F
Arch Iran Med; 2016 Feb; 19(2):141-6. PubMed ID: 26838086
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
Morga A; Ajmera M; Gao E; Patterson-Lomba O; Zhao A; Mancuso S; Siddiqui E; Kagan R
Menopause; 2024 Jan; 31(1):68-76. PubMed ID: 38016166
[TBL] [Abstract][Full Text] [Related]
13. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2004; 11(1):11-33. PubMed ID: 14716179
[TBL] [Abstract][Full Text] [Related]
14. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
Fraser GL; Lederman S; Waldbaum A; Kroll R; Santoro N; Lee M; Skillern L; Ramael S
Menopause; 2020 Apr; 27(4):382-392. PubMed ID: 32102086
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
Constantine GD; Revicki DA; Kagan R; Simon JA; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):513-519. PubMed ID: 30516713
[TBL] [Abstract][Full Text] [Related]
16. Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
Pinkerton JV; Simon J; Panay N; Seitz C; Parke S; Caetano C; Mellinger U; Haseli Mashhadi N; Haberland C; Atanackovic G; Holz C; Mao G; Morrison M; Nisius S; Schaefers M; Zuurman L
Menopause; 2024 Jun; 31(6):522-529. PubMed ID: 38564691
[TBL] [Abstract][Full Text] [Related]
17. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.
Cobin RH; Goodman NF;
Endocr Pract; 2017 Jul; 23(7):869-880. PubMed ID: 28703650
[TBL] [Abstract][Full Text] [Related]
18. A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women.
Blümel JE; Chedraui P; Baron G; Belzares E; Bencosme A; Calle A; Danckers L; Espinoza MT; Flores D; Gomez G; Hernandez-Bueno JA; Izaguirre H; Leon-Leon P; Lima S; Mezones-Holguin E; Monterrosa A; Mostajo D; Navarro D; Ojeda E; Onatra W; Royer M; Soto E; Tserotas K; Vallejo S;
Menopause; 2011 Jul; 18(7):778-85. PubMed ID: 21407137
[TBL] [Abstract][Full Text] [Related]
19. Systematic review of neurokinin-3 receptor antagonists for the management of vasomotor symptoms of menopause.
Cieri-Hutcherson NE; Marji EK; Hutcherson TC
Menopause; 2024 Apr; 31(4):342-354. PubMed ID: 38471077
[TBL] [Abstract][Full Text] [Related]
20. Managing vasomotor symptoms in women after cancer.
Pinkerton JV; Santen RJ
Climacteric; 2019 Dec; 22(6):544-552. PubMed ID: 31081391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
